NDATOPICALLOTION
Lifecycle
Pre-Launch
Clinical Trials
1
Data completeness
3/8 — Basic
MONISTAT-DERM (miconazole nitrate) by Sight Sciences is clinical pharmacology miconazole nitrate exhibits fungicidal activity in vitro against species of the genus candida.
Drug data last refreshed 12h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MONISTAT-DERM is a topical miconazole nitrate lotion indicated for fungal skin infections, particularly vulvovaginal candidiasis. It exhibits fungicidal activity against Candida species through an unknown pharmacologic mechanism. The drug is in pre-launch stage under NDA review by Sight Sciences.
Pre-Launch
Pre-launch stage offers ground-floor opportunity to build brand infrastructure and establish market position in the topical antifungal segment.
Mechanism of Action
CLINICAL PHARMACOLOGY Miconazole nitrate exhibits fungicidal activity in vitro against species of the genus Candida. The pharmacologic mode of action is unknown. Following intravaginal administration of miconazole nitrate, small amounts are absorbed. Administration of a single dose of miconazole…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Prospective Two-Year Study to Assess Miconazole Nitrate Resistance in Neonates and Infants
Started May 2007
200 enrolled
Diaper Rash
Worked on MONISTAT-DERM at Sight Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.